
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is positioned around a focused late-stage pancreatic cancer strategy, concentrating Ampligen on a disease that still caused more than 100,000 deaths in the American and European Union markets and more than 450,000 worldwide as recently as 2022. The ongoing DURIPANC Phase 2 study, run with AstraZeneca and Erasmus MC, has enrolled 18 subjects and produced an encouraging clinical backdrop, while key data on benefit is expected in Q1 2027 and overall survival in Q3 2027. Fundamentally, the upside thesis is supported by multiple active trials, positive early data, a Q1 2026 net loss of $3.0 million, $6 million in cash against $4 million of debt, and a valuation that appears to understate the potential of its oncology pipeline.
Bears say
AIM ImmunoTech is an early-stage, clinical drug development company with minimal revenue, which leaves it highly dependent on future clinical and regulatory progress rather than recurring commercial cash flow. On August 10, it reported Q2 2026 results showing a $7 million net loss, or $(0.43) per share, materially worse than the $(0.12) to $(0.17) estimates, underscoring weak operating leverage and ongoing cash burn. The negative outlook is driven by balance sheet and liquidity risk, uncertainty around Ampligen and other candidates proving safety and efficacy, and the added difficulty of securing approval, reimbursement, and commercialization in a competitive biotech market.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AIM ImmunoTech Inc (AIM) Forecast
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares